US FDA Approves StemCyte Biologics License Application for REGENECYTE^™ Cord Blood Cell Therapy Product

StemCyte Inc. announced that the US FDA has approved the Biologics License Application for its HPC, Cord Blood product REGENECYTE™, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders.